`
`IMMUNOGEN 2213, pg. 1
`Phigenix v. Immunogen
`IPR2014-00676
`
`
`
`NDA 20-896Page 2is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FINAL PRINTEDLABELING" for approved NDA 20-896. Approval of this submission by FDA is not requiredbefore the labeling is used.Should additional information relating to the safety and effectiveness of the drug becomeavailable, revision of that labeling may be required.We remind you of the Phase 4 commitments specified in your submission dated April 16, 1998.These commitments are listed below.(b)(4)CC----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------Protocols, data, and final reports, should be submitted to your IND for this product and a copy ofthe cover letter sent to this NDA. In addition, we request under 21 CFR 314.81(b)(2)(vii) thatyou include in your annual report to this application, a status summary of each commitment. Thestatus summary should include the number of patients entered in each study, expected completionand submission dates, and any changes in plans since the last annual report. For administrativepurposes, all submissions, including labeling supplements, relating to these Phase 4 commitmentsmust be clearly designated "Phase 4 Commitments".Further, we acknowledge your April 9 and 14, 1998 commitments to address the following
`
`IMMUNOGEN 2213, pg. 2
`Phigenix v. Immunogen
`IPR2014-00676
`
`
`
`NDA 20-896Page 3chemistry, manufacturing and controls concerns with due diligence:1. Three batches of each dosage strength Xeloda (capecitabine) Tablets manufactured using theimproved manufacturing process will be placed on stability, and the data will be included inthe annual report. 2. Within one year, R(b)(4)CC---------------------ined from commercially manufactured lots ofcapecitabine will be reviewed and compared to the current specifications to determine howthese specifications can be tightened. Revised specifications will be developed and submittedin a pre-approval supplement.We also remind you that, under 21 CFR 314.550, after the initial 120 day period following thisapproval, you must submit all promotional materials, including promotional labeling as well asadvertisements, at least 30 days prior to the intended time of initial dissemination of the labelingor initial publication of the advertisement.Validation of the regulatory methods has not been completed. At the present time, it is the policyof the Center not to withhold approval because the methods are being validated. Nevertheless,we expect your continued cooperation to resolve any problems that may be identified.Please submit one market package of the drug product when it is available.We remind you that you must comply with the requirements for an approved NDA set forth under21 CFR 314.80 and 314.81.If you have any questions, please contact Maureen Pelosi, Project Manager, at (301) 594-5768.Sincerely yours,Robert Temple, M.D.DirectorOffice of Drug Evaluation ICenter for Drug Evaluation and ResearchENCLOSURE
`
`IMMUNOGEN 2213, pg. 3
`Phigenix v. Immunogen
`IPR2014-00676
`
`